The factor Xa inhibitor rivaroxaban reduces cardiac dysfunction in a mouse model of myocardial infarction

Thrombosis Research
Michael F BodeNigel Mackman

Abstract

Rivaroxaban selectively inhibits factor Xa (FXa), which plays a central role in blood coagulation. In addition, FXa activates protease-activated receptor-2 (PAR-2). We have shown that PAR-2-/- mice exhibit less cardiac dysfunction after cardiac injury. Wild-type (WT) and PAR-2-/- mice were subjected to left anterior descending artery (LAD) ligation to induce cardiac injury and heart failure. Mice received either placebo or rivaroxaban chow either starting at the time of surgery or 3 days after surgery and continued up to 28 days. Cardiac function was measured by echocardiography pre-surgery and 3, 7 and 28 days after LAD ligation. We also measured anticoagulation, intravascular thrombi, infarct size, cardiac hypertrophy and inflammation at various times. Rivaroxaban increased the prothrombin time and inhibited the formation of intravascular thrombi in mice subjected to LAD ligation. WT mice receiving rivaroxaban immediately after surgery had similar infarct sizes at day 1 as controls but exhibited significantly less impairment of cardiac function at day 3 and beyond compared to the placebo group. Rivaroxaban also inhibited the expansion of the infarct at day 28. Rivaroxaban did not significantly affect the expression of inflamm...Continue Reading

References

Jun 1, 1995·Journal of Molecular and Cellular Cardiology·J P CleutjensK T Weber
Apr 25, 2000·American Journal of Physiology. Heart and Circulatory Physiology·P GolinoM Chiariello
Apr 5, 2003·Arteriosclerosis, Thrombosis, and Vascular Biology·Christopher D MajorPatricia Andrade-Gordon
May 16, 2003·The New England Journal of Medicine·Mariell Jessup, Susan Brozena
Mar 17, 2004·Heart·Stefan D Anker, Stephan von Haehling
Nov 27, 2004·Experimental Biology and Medicine·Matthew J FlickJay L Degen
Mar 8, 2005·Journal of Thrombosis and Haemostasis : JTH·E PerzbornA Straub
Aug 17, 2005·Journal of Thrombosis and Haemostasis : JTH·S R Coughlin
Oct 31, 2007·Circulation·Rafal PawlinskiNigel Mackman
May 16, 2008·The New England Journal of Medicine·Eugene Braunwald
Nov 28, 2008·Journal of Thrombosis and Haemostasis : JTH·S T B G LoubeleH ten Cate
Aug 21, 2010·Arteriosclerosis, Thrombosis, and Vascular Biology·Silvio AntoniakRafal Pawlinski
Dec 22, 2011·Thrombosis and Haemostasis·Meyer Michel SamamaUNKNOWN Rivaroxaban Anti-Factor Xa Chromogenic Assay Field Trial Laboratories
Feb 9, 2013·The Journal of Clinical Investigation·Silvio AntoniakNigel Mackman
Oct 17, 2013·Cardiovascular Research·Bernhard UnsöldGerd Hasenfuß
Dec 7, 2013·PloS One·Silvio AntoniakRafal Pawlinski
Dec 19, 2013·Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism·Robert PloenRoland Veltkamp
Dec 9, 2015·Journal of Molecular and Cellular Cardiology·Mikhail A KolpakovAbdelkarim Sabri
Apr 30, 2016·Journal of the American College of Cardiology·Peter C WestmanStephen E Epstein
Jun 11, 2016·Arteriosclerosis, Thrombosis, and Vascular Biology·Yuji OeNobuyuki Takahashi
Jun 19, 2016·Thrombosis Research·Christi M TerryAlfred K Cheung
Oct 11, 2017·Journal of cardiology·Hidekazu KondoNaohiko Takahashi
Mar 31, 2018·Arteriosclerosis, Thrombosis, and Vascular Biology·Shannon M JonesA Phillip Owens

❮ Previous
Next ❯

Citations

Dec 26, 2018·Arteriosclerosis, Thrombosis, and Vascular Biology·Jens J PosmaNigel Mackman
Aug 9, 2019·Journal of Thrombosis and Haemostasis : JTH·Anaum MaqsoodNigel Mackman
Jun 5, 2020·Journal of the American Heart Association·Yoshikazu YokonoHirofumi Tomita
Jul 22, 2021·Hypertension Research : Official Journal of the Japanese Society of Hypertension·Masato NaritaHirofumi Tomita
Aug 6, 2021·Hypertension Research : Official Journal of the Japanese Society of Hypertension·Masaki Mogi

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Inflammation

Inflammation plays a significant role in the development of cardiovascular diseases, an understanding of these endogenous processes is critical for evaluating the risks and potential treatment strategies. Discover the latest research on cardiovascular inflammation here.

Biomarkers for Cardiovascular Risk Assessment

Sensitive and accurate biomarkers used in cardiovascular risk prediction can potentially be used to manage the risk of cardiovascular disease. Discover the latest research on Biomarkers for Cardiovascular Risk Assessment here. Discover the latest research on Biomarkers for Cardiovascular Risk Assessment here.

Cardiomegaly

Cardiomegaly, known as an enlarged heart, is a multifactorial disease with different pathophysiological mechanisms. Hypertension, pregnancy, exercise-induced and idiopathic causes are some mechanisms of cardiomegaly. Discover the latest research of cardiomegaly here.

Cardiotoxicity

Cardiotoxicity refers to the muscle damage or dysfunction of heart electrophysiology caused by drug intake or due to disease complications. It is a well-known side effect of several cytotoxic drugs, especially of the anthracyclines and can lead to long term morbidity. Here is the latest research.

Blood Clotting Disorders

Thrombophilia includes conditions with increased tendency for excessive blood clotting. Blood clotting occurs when the body has insufficient amounts of specialized proteins that make blood clot and stop bleeding. Here is the latest research on blood clotting disorders.